Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (ALNY) and BioLife Solutions (BLFS) w...

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and BioLife Solutions (BLFS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alnylam Pharma (ALNY), Biomea Fusion (BMEA) and Maze...

Analysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Biomea Fusion (BMEA)

In a report released today, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Alnylam Pharma, with a price target of $429.00. Ijem cov...

Alnylam Pharma (ALNY) Gets a Buy from Canaccord Genuity

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Fractyl Health, Inc. (GUTS), AbSci (ABSI) and Alnylam Pharma (ALN...

Analysts Conflicted on These Healthcare Names: Fractyl Health, Inc. (GUTS), AbSci (ABSI) and Alnylam Pharma (ALNY)

William Blair analyst Myles Minter reiterated a Buy rating on Alnylam Pharma today and set a price target of $308.05. According to TipRanks, Minter...

Current Quarter	$0.95	Next Quarter	$1.38
Current Year	$6.7	Next Year	$10.64
QoQ Growth	+45.3%	YoY Growth	+58.8%
3Y EPS CAGR	+32.9%	Target Price	$450.43
Consensus	Buy	Upside	+38.3%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ALNY	$325.64	+1.92%	650.12K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ALNY	$325.64	+1.9%	650.12K
3
4
5
6

ALNY

ALNY

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Alnylam Pharmaceuticals Inc. Data in Excel

Get Alnylam Pharmaceuticals Inc. Data in Excel